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ABSTRACT
Radiation therapy (RT) is a valid treatment option for head and neck cancer 
(HNC). The risk of RT-induced toxicities is significant, especially due to extended 
treatment fields. The raise in amylase activity is strictly dependent on the volume of 
salivary glands included in the irradiated target volume and it is firmly related to the 
dose. The aim of this review is to report the effects on salivary amylase activity after 
radiation exposure of salivary glands, in patients with HNC.
INTRODUCTION
Radiotherapy (RT) represents one of the classical 
options for managing head and neck cancer (HNC). 
Radiation effects on salivary glands are of particular 
interest in clinical practice. Generally, salivary glands, 
especially parotid glands, show a high sensitivity to 
ionizing radiations, although they have a very low 
proliferative activity [1]. The increase in serum salivary 
amylase secondary to salivary glands irradiation is 
of considerable radiobiological and radiotherapeutic 
significance. This phenomenon has been mainly ascribed 
to the disruption of serous cells and changes in their 
cell membrane permeability resulting in intracellular 
amylase release. Ionizing radiations cause loss of acinar 
architecture, inflammatory cell infiltration and disruption 
or vacuolation of serous cells [2].
The purpose of this narrative review is to provide an 
updated description of early irradiation effects on salivary 
glands in HNC. We focus on variations of serum salivary 
amylase after RT. We will briefly introduce the salivary 
amylase property in an attempt to provide a means of 
understanding how it relates specifically to irradiation. 
We give a summary of clinical research focused on 
evaluating changes in serum amylase levels. It represents a 
distinctive opportunity for learning more about the clinical 
radiobiology of salivary amylase during and after RT in 
HNC patients. 
Basic knowledge of salivary amylase
Saliva plays a central role in dental and oral care, 
in lubricating mucosa, in contributing to antimicrobial 
activity and facilitating eating. Submandibular glands 
produce about 70% of saliva, whereas 20% of saliva is 
secreted by parotid glands and approximately 10% by 
minor salivary glands [3]. Saliva has a crucial roles in 
food boli preparation and digestion [4]. Saliva contains 
several proteins involved in digestive process and salivary 
amylase is the most abundant components. Salivary 
amylase is mainly produced in the parotid gland and it is 
responsible for starch hydrolysis, initiating carbohydrate 
digestion in the oral cavity. It is a calcium-containing 
metallo-enzyme that hydrolyzes the α-(l,4)-linkages of 
starch to glucose and maltose [5]. The molecular weight 
is about 55,000 and the whole saliva may contain 0.04 
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to 0.4 mg/ml amylase [6]. Salivary amylase level varies 
during the day, from individual to individual, depends on 
different regions in the oral cavity and tends to diminish 
with old age. Salivary amylase concentration can be 
detected in the blood. The reference range for serum 
amylase is 40–140 U/L. But serum amylase is produced 
by both salivary glands and exocrine pancreas at almost 
equal proportion [4]. The most accurate method for 
distinguishing salivary amylase from pancreatic amylase 
is the isoamylase analysis by agarose gel electrophoresis 
[7]. On agarose gel electrophoresis, the mobility of the 
more anionic isoenzyme is related to salivary amylase, 
whereas the less anionic band corresponds to pancreatic 
amylase. Physiologically, based on carbohydrate content, a 
total of five isoenzymes are determined, three isoenzymes 
of salivary amylase (which contain carbohydrates) and 
two isoenzymes of pancreatic amylase (which no contain 
carbohydrates) [8].
According to a classical view, elevated concentration 
of digestive enzymes in the serum, including amylase and 
lipase, can suggest an inflammatory diseases such as acute 
pancreatitis. Whereas elevation in serum amylase levels 
with no increase in serum lipase concentration or apparent 
pancreatic disorder can be used in the diagnosis of salivary 
glands inflammation or acute stress.
Salivary amylase: the radiobiological properties
Post RT hyperamylasemia is almost only related 
to salivary glands irradiation [9]. Although irradiation-
induced damage in salivary gland was first described 
in 1911, its mechanism is still a de- bate [10]. Salivary 
glands tissue is largely differentiated and metabolically 
active with a low mitotic rate and no expected future 
mitoses [11]. Thus, based on Bergonie and Tribondeau 
radiosensitivity law, salivary glands are presumably 
radioresistant. Radiation-effect on mechanisms of 
salivary gland radiosensitivity has been tested mainly in 
parotid glands, whereas submandibular, sublingual and 
minor salivary glands have been studied lesser in term 
of response to irradiation. Based on experiments with 
rodents and especially with rats, the regional differences in 
their parotid gland radiosensitivity have been considered 
as plausible model for human circumstances [12]. The 
cranial part of the parotid gland is more radiosensitive 
than the caudal part. Ionizing radiation induces damage to 
muscarinic receptors involved in secretary responsiveness, 
with consequent destruction of serous cells [13]. Secretory 
granules of serous cells are rich in proteolytic enzymes. 
This characteristic can justify the high radiosensitivity of 
the parotid glands, which contain much higher level of 
mucous cells, compared with the relative radioresistance 
of the other salivary glands [3]. 
The time kinetics of damage is expressed in two 
phases: at first (0–60 days) salivary gland dysfunction 
depends on plasma membrane damage, later (60–240 days) 
on “traditional” killing of progenitor cells [14]. Figure 1 
summarizes salivary amylase kinetics after irradiation, 
using a qualitative curve. Irradiation of the salivary glands 
determines a rapid increase in the serum amylase within a 
few hours after irradiation and a return to normal levels in 
the subsequent days. During the acute phase of radiation 
damage, within few hours after dose up to 4 Gy, the 
amylase secretion is quickly affected, with a 10 to 80 fold 
increase of the serum value. This phenomenon reaches 
its peak within 12–36 hours and it seems to be a direct 
consequence of acinar cells impairment [11]. Later on the 
amylase production  deteriorates, due to newly formed 
acinar cells that are unable to work properly. Therefore, 
hyperamylasemia represents a very early change in serous 
salivary cells, that loss their ability to produced amylase. 
Radiation therapy and salivary amylase: the 
clinical trials
Few studies are available in literature investigating 
early radiation-induced amylase changes in HNC patients 
(Table 1). Globally, they described some correlation 
between the degree of amylase rise found in the serum 
and the amount of salivary tissue included in the treatment 
Figure 1: Qualitative representation of salivary amylase kinetics after irradiation.
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volume. The increase in enzyme activity, as well as its 
peak value, depends on the fractionation modality. It 
is higher and appears earlier with an increasing daily 
delivered total dose. The vast majority of data involved 
parotid glands, due to their well-documented amylase 
activity, instead of submandibular, sublingual and minor 
salivary glands.
Leslie et al. measured serum amylases prior and 
at 24-h intervals following the start of RT in patients 
with locally advanced HNC [2]. Treatment plan included 
opposed fields in order to cover the whole neck up to 
above the hard palate. Thus all the major salivary glands 
were included in the treatment volume. Two different 
fractionation schedules were used, including continuous 
hyperfractionated accelerated RT and conventional 
fractionated RT. Marked rises in the serum amylase 
were seen in all these patients peaking 24–48 hours 
after the irradiation and then falls rapidly reaching 
normal levels. The peak rise in serum amylase was 
greater in hyperfractionated accelerated schedule than in 
conventional fractionated RT  (mean peak 4477 IU/l and 
3275 IU/l, respectively). Similar results were obtained 
by Kashima et al. [15] and Borok et al. [16]. Kashima 
et al. analyzed 33 patients with HNC cancer and noted 
a transient hyperamylasemia after a dose range of 
1–2.75 Gy, with a peak elevation at 9–36 hours after RT 
[15]. Borok et al. measured serum amylase levels in 12 
consecutive HNC patients treated with fractionated doses 
from 1.8 to 4 Gy per day in accordance with patient’s 
needs [16]. Rapid transient increases in enzyme activity, 
limited to the first days of RT, were consistently found. 
Interestingly, van den Brenk et al. [17] studied the effects 
of steroids administration on post-RT changes in serum 
amylase, in order to protect salivary tissues from radiation 
damage. Results were obtained in 12 patients with HNC 
receiving 100 or 200 mg prednisolone intravenously 
approximately 20 minutes before the first RT fraction. 
Prednisolone reduced the post-RT hyperamylasaemic 
response compared with that following the second 
fraction in which prednisolone was not administered 
before treatment. Perhaps, the steroid decreased damage 
to salivary tissue, by influencing the labilisation and 
stabilisation of lysosomal membranes. However, little 
evidence has been provided to support the hypothesis that 
prednisolone should be administered in a prophylactic way. 
TBI represents a situation not generally encountered 
in HNC clinical practice. In fact, HNC patients are treated 
with RT fractionated doses: a conventional fractionation 
of 2 Gy per day, five times a week, or a hypofractionated 
scheme with a simultaneously integrated boost (SIB) 
technique. The parotid glands received at least 2 Gy per 
day. However, HNC treatment that includes salivary gland 
in the target volume, had a similar rise in amylasemia 
as did TBI patients who had received the same dose. 
Published data concerning acute effects after TBI are also 
consistent with dose-response relationship. Junglee et 
al. [18] tested whether TBI may cause different changes 
in pancreatic and salivary amylase serum concentration. 
Six leukemic patients received TBI (total dose 7.5 Gy) 
before bone marrow transplantation. Biochemical results 
demonstrated that salivary amylase activity increased 
by 21 to 51 fold the basal value, peaking on the first 
day after TBI and returning to normal within five days. 
Whereas the pancreatic enzymes after irradiation 
showed minimal or no change. The increase of salivary 
amylase was associated with the development of clinical 
parotitis. All patients reported swelling in parotid and 
submandibular glands region immediately after TBI and 
it subsided over 24–36 hours. Analogous results were 
previously defined by Barrett et al. [19]. Most of the 
serum amylase increase derived from salivary damage, 
with a much smaller pancreatic component. This rise was 
associated with symptoms of acute parotitis in all 12 acute 
leukaemia patients undergoing TBI (total dose 10 Gy) for 
bone marrow trasplantation. At Institut Gustave-Roussy, 
Hennequin et al. studied amylasemia in 38 patients [9]. Of 
these patients, 15 patients received TBI for bone marrow 
grafting at various dose levels (10 Gy, 2 Gy, 1.35 Gy); 
10 patients received a localized irradiation of 2 Gy in the 
Waldeyer ring and the remainder 13 patients had a localized 
pancreatic irradiation. Hyperamylasemia was found to be 
constant and dose-dependent in TBI and Waldeyer ring 
patients. In contrast, patients given a pancreatic irradiation 
did not show any increase in amylasemia. Dubray et al. 
[20] measured serum salivary amylase before and 24 
h after either TBI (31 patients) or localized irradiation 
including the salivary glands (40 patients) or the pancreatic 
area (22 patients). They proposed, on the basis of a simple 
mathematical model of the increase in amylasemia, that 
irradiation of salivary glands predicted a maximum 
amylasemia level for doses larger than 4 Gy and smaller 
than 10 Gy, given in a fractionated setting. They stressed 
that post-RT hyperamylasemia is a good criterion for triage 
of accidentally irradiated patients.
Table 1: Clinical head and neck studies on serum amylase increase
Author Patient population (n) Salivary amylase peak (after first RT fraction)
Leslie [2] head and neck cancer (41) 24–48 hours
Kashima [15] head and neck cancer (33) 9–36 hours
Borok [16] head and neck cancer (12) 48–96 hours
RT: radiotherapy.
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Consideration
The usual total RT dose given to HNC ranges 
between 60–70 Gy (2 Gy fraction) and it depends on 
stage disease at diagnosis and subsequent multimodality 
treatment approach. Last decades are characterized by 
improvement in RT technology and this guarantees higher 
rates of salivary glands sparing. In RT of the head and 
neck region, the parotid gland tissue is one of the most 
critical dose-limiting organs. Well-known side effects, 
such as xerostomia, dental caries and osteoradionecrosis, 
are routinely observed, whereas the effect of salivary 
gland tissue irradiation on serum amylase levels received 
relatively little attention. RT induces an acute increase in 
salivary amylase in serum and patient can show clinical 
evidence of parotitis consistent with it. For instance, 
based on PARSPORT trial data, intensity modulated RT 
(IMRT), compared with conventional 3-dimensional RT, 
significantly reduced the incidence of xerostomia and 
resulted in better recovery of saliva secretions [21]. But 
detailed analysis of amylase quantitative measurements 
was not recorded. The reduction in parotid cell production 
of saliva may be related with decreased production of 
amylase enzyme as well. A relationship between acute 
increase and chronic decrease in serum salivary amylase 
and subsequent xerostomia is logical but has not been 
established. This event could be associated to late toxicity, 
which makes a great impact on clinical evaluation and 
results from a different radiation targets within the tissue. 
Further studies are needed to verify if any long term 
changes in salivary amylase levels occur. Probably serum 
salivary amylase could be used as a biological indicator. 
Its dose-effect relationship needs to be more precisely 
defined, especially because of a considerable inter-
individual variability. Measurement of amylase activity 
may be used as an end point for radiation damage in HNC 
patients to identify patients at increased or decreased risk 
for RT-related injury. An indicator of radiation tolerance 
could be increasingly important due to the growing 
number of HNC treatment survivors. It would maximize 
individual therapeutic gain.
CONCLUSIONS
Serum salivary amylase biochemical changes after 
irradiation in HNC patients are less commonly appreciated 
in clinical trials. At present, no consistent and validated 
predictive assay exists that is able to definitively associate 
salivary amylase alteration to salivary gland damage. 
Actually, the information obtained from the published 
studies is limited and most of the available references 
are old, which might mean the topic is not frontier 
research. But we believe that serum salivary amylase 
activity is valuable to a certain extent to clinical measure. 
An improved understanding of the radiobiological 
mechanism, as well as appropriate clinical data collection, 
could represent the key to construct appropriate dose-
effect curves to assess the degree of radiation-induced 
damage in HNC clinical practice.
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